Aquatic training vs land‐based training
Physical function · adults with fibromyalgia
1 finding from 1 review
- no estimate extracted2 studies · 74 participantsVery low
Findings
What do systematic reviews say?
3,006 questions · 3,171 findings · 607 reviews · Headline outcomes only
No studies found 411 · 13%GRADE not reported 153 · 4.8%Very low 968 · 30.5%Low 897 · 28.3%Moderate 589 · 18.6%High 153 · 4.8%
Erythropoietin (subcutaneous or intravenous at varying dosages) vs placebo
Withdrawals due to high blood pressure · anemia in patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
- Erythropoiesis‐stimulating agents for anemia in rheumatoid arthritis 2013 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intervention not reported
High dose SSRIs versus placebo Continuous administration · women with premenstrual syndrome
The intervention probably leads to higher high dose SSRIs versus placebo Continuous administration (moderate certainty).
1 finding from 1 review
- Selective serotonin reuptake inhibitors for premenstrual syndrome 2013 · Cochrane Headline outcomes onlyRR 6.35 [2.88, 14]1 study · 231 participantsModerate
PIMOZIDE + ANY ANTIPSYCHOTIC vs antipsychotics
Quality of life (change from baseline) in the medium term · patients with schizophrenia or related psychoses
1 finding from 1 review
- no estimate extracted1 study · 53 participantsGRADE not reported
STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES
Leaving the study early (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. standard higher dose (>… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
- RR 0.12 [0.01, 2.12]2 studies · 64 participantsVery low
STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES
Leaving the study early · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. high dose (> 15‐35 mg/day) compared with OTHER DOSES (very low certainty).
1 finding from 1 review
- RR 0.78 [0.47, 1.28]4 studies · 191 participantsVery low
STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES
Global state: No clinically significant response (as defined by the original studies) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
- RR 1.09 [0.67, 1.75]1 study · 48 participantsVery low
STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES
Global state: 1. No clinically significant response in global state (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
- RR 0.95 [0.75, 1.19]2 studies · 81 participantsVery low
STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
- RR 0.12 [0.01, 2.12]2 studies · 64 participantsVery low
STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
- RR 0.59 [0.45, 0.78]3 studies · 144 participantsVery low
Intervention not reported
Hospital length of stay (high‐risk surgical patients) · Adult patients in intensive care
1 finding from 1 review
- Pulmonary artery catheters for adult patients in intensive care 2013 · Cochrane Headline outcomes onlyno estimate extracted5 studies · 503 participantsHigh
Electromagnetic field treatment vs placebo
Pain VAS 0‐100 (higher means worse) · patients with osteoarthritis
1 finding from 1 review
- no estimate extracted6 studies · 434 participantsModerate
Electromagnetic field treatment vs placebo
Function (short‐term) WOMAC scale from: 0 to 100 (higher is worse function). · patients with osteoarthritis
1 finding from 1 review
- no estimate extracted3 studies · 197 participantsLow
Oral NSAIDs vs placebo
Functional disability at 3 months ‐ not measured · Adults with lateral elbow pain
1 finding from 1 review
- Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults 2013 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 292 participantsLow
Intervention not reported
Arrhythmias ‐ high risk patients · Adult patients 18 years and above undergoing elective surgery
1 finding from 1 review
- Pharmacological agents for preventing morbidity associated with the haemodynamic response to tracheal intubation 2013 · Cochrane Headline outcomes onlyno estimate extracted9 studies · 337 participantsModerate
Intervention not reported
Myocardial Ischaemia ‐ high risk patients · Adult patients 18 years and above undergoing elective surgery
1 finding from 1 review
- Pharmacological agents for preventing morbidity associated with the haemodynamic response to tracheal intubation 2013 · Cochrane Headline outcomes onlyno estimate extracted12 studies · 395 participantsModerate
Intervention not reported
Attitudes towards relationship violence (0‐12 months) (higher score = less accepting of dating violence) · adolescents and young adults (aged 12‐25 years)
1 finding from 1 review
- Educational and skills‐based interventions for preventing relationship and dating violence in adolescents and young… 2013 · Cochrane Headline outcomes onlyno estimate extracted22 studies · 5256 participantsModerate
Intervention not reported
Behaviour in relationship violence (0‐12 months) (higher score = more positive behaviour) · adolescents and young adults (aged 12‐25 years)
1 finding from 1 review
- Educational and skills‐based interventions for preventing relationship and dating violence in adolescents and young… 2013 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 887 participantsModerate
Intervention not reported
Knowledge of relationship violence (0‐12 months) (higher score = better knowledge) · adolescents and young adults (aged 12‐25 years)
1 finding from 1 review
- Educational and skills‐based interventions for preventing relationship and dating violence in adolescents and young… 2013 · Cochrane Headline outcomes onlyno estimate extracted10 studies · 6206 participantsModerate
Intervention not reported
Skills related to relationship violence (0‐12 months) (higher score = better skills) · adolescents and young adults (aged 12‐25 years)
1 finding from 1 review
- Educational and skills‐based interventions for preventing relationship and dating violence in adolescents and young… 2013 · Cochrane Headline outcomes onlyno estimate extracted7 studies · 1369 participantsModerate